Prostate cancer (PC) is one of the most common malignancies and the most common cause of death in men from cancer worldwide. In the initial stages, the disease may be asymptomatic or symptomatic due to associated, more common pathologies such as chronic prostatitis, benign prostatic hyperplasia. Early diagnosis of PC allows for timely treatment, which contributes to the full recovery of patients.

In recent decades, prostate-specific antigen (PSA) has been the only widely used marker of prostate cancer. As a result of the search for new markers of PC in tissues and blood, several technologies were applied, which gave their result.

An increase in the level of expression of the TMPRSS2-ERG or T2E gene in urine in patients with PC was revealed. A group of scientists led by Tomlins SA in their analysis concluded that up to 55% of prostate cancer cases have overexpression of ERG. In addition, overexpression of ERG in most tumors is due to